A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts (opens original article in a new tab)

Global conflicts and geopolitical tensions are threatening the supply chains for a $30 billion cancer treatment market, as companies seek alternative sources for radioactive materials.

• Global conflicts and geopolitical tensions threaten the supply chains for radioligand therapy, a $30 billion cancer treatment market.
• Russia-Ukraine war, China's rare earth controls, and Iran turmoil are disrupting access to radioactive materials needed for cancer treatments.
• Companies like Novartis and ITM are seeking alternative suppliers and production methods to mitigate risks from global conflicts.